Photo of Anne Johnson Palmer

Anne, a partner in the San Francisco office, has extensive experience in complex commercial litigation matters, with a particular emphasis on class action litigation and corporate disputes. Her practice includes front-line representation in consumer and securities class actions, shareholder derivative actions, and M&A and transaction-related litigation. In addition to representing public companies as well as private equity firms and their portfolio companies in such matters, Anne has led clients through a range of commercial disputes involving unfair competition, antitrust, consumer protection, and business tort claims.

Anne is also a core member of the firm’s data privacy and cybersecurity practice. She has guided clients through forensic investigations and incident response efforts in the wake of large data breaches, and in defending the class action litigation that frequently follows. Anne is part of the firm’s dedicated working group focused on the California Consumer Privacy Act (CCPA). She has counseled clients on how to assess and mitigate the litigation risks introduced by the CCPA, and has presented on the new law at client roundtables that the firm has hosted around the country.

Anne has appeared in federal and state courts in California and a number of other jurisdictions, and in multidistrict litigations. In 2018, Anne was recognized by the Daily Journal in its “Top 40 Under 40” list of leading California attorneys. Anne is a member of the Women’s Forum Steering Committee at Ropes & Gray, and serves as one of the Hiring Partners for the firm’s San Francisco office.

Nguyen v. Endologix, Inc., 2020 WL 3069776 (9th Cir. June 10, 2020)

On June 10, 2020, the Ninth Circuit affirmed the dismissal of a putative securities fraud class action brought against a medical device corporation, Endologix, Inc., and certain of its officers, regarding statements concerning the FDA’s likelihood of premarket approval of the Company’s aneurysm sealing product, Nellix. The Court held that plaintiff failed to allege facts giving rise to a strong inference of scienter (i.e., fraudulent intent) and thus failed to adequately plead a claim for securities fraud.

Continue Reading Ninth Circuit Affirms Dismissal of Action Regarding Statements Concerning Likelihood of FDA Premarket Approval of Aneurysm Sealing Device